Full text
Earnings transcript
Read the complete earnings call transcript.
PFE
Pfizer Inc.
$28.33
-0.22
(-0.77%)
| Exchange: | NYSE |
| Market Cap: | 161.092B |
| Shares Outstanding: | 4.141B |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Albert Bourla | |||||
| Full Time Employees: | 81000 | |||||
| Address: |
| |||||
| Website: | https://www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 59,553,000 | 63,627,000 | 62,579,000 |
| Gross Profit | 30,340,000 | 41,846,000 | 44,014,000 |
| EBITDA | 9,557,000 | 18,127,000 | 15,096,000 |
| Operating Income | 5,292,000 | 16,483,000 | 15,437,000 |
| Net Income | 2,133,000 | 8,020,000 | 7,770,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 226,501,000 | 213,396,000 | 0 |
| Total Liabilities | 137,213,000 | 124,899,000 | -93,096,000 |
| Total Stockholders Equity | 89,014,000 | 88,203,000 | 93,096,000 |
| Total Debt | 70,845,000 | 63,649,000 | 0 |
| Cash and Cash Equivalents | 2,853,000 | 1,043,000 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 8,700,000 | 12,744,000 | 0 |
| Capital Expenditure | -3,907,000 | -2,909,000 | 0 |
| Free Cash Flow | 4,793,000 | 9,835,000 | 0 |
| Net Income | 2,172,000 | 8,051,000 | 7,771,000 |
| Net Change in Cash | 2,449,000 | -1,810,000 | -1,107,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 50,069,895.526 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 52,946,838.541 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 51,574,750 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 14,764,398.436 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 15,612,739.191 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 15,208,143.541 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 12,144,101.942 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 13,059,491.082 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 12,622,920.002 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 9,705,702.310 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 10,263,377.779 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 9,997,407.923 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 2.220 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 2.300 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 2.140 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 10 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 6 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: Pfizer reported Q3 2025 revenues of $16.7 billion, reflecting a 7% operational increase year-over-year, driven by strong sales in key therapeutic areas as highlighted in the earnings call transcript. This demonstrates resilience in core product lines amidst competitive pressures.
- Strong R&D Pipeline: The earnings call emphasized a focus on innovation, with significant investments in research and development yielding promising candidates in oncology and rare diseases, positioning Pfizer for sustained long-term growth.
- Solid Financial Position: Analysis of balance sheet data indicates a healthy level of cash and cash equivalents alongside manageable total current liabilities, providing financial flexibility for strategic initiatives and dividend payments (dividend yield TTM noted as a key metric).
- Global Market Presence: Revenue geographic segments reveal a diversified revenue base across multiple regions, reducing dependency on any single market and enhancing stability against regional economic fluctuations.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates PFE intrinsic value between $25.39 – $59.26 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about PFE valuation
Is Pfizer Inc. (PFE) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Pfizer Inc. (PFE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is PFE a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PFE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is PFE’s P/E ratio?
You can see PFE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for PFE?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is PFE a good long-term investment?
Whether PFE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
PFE
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.77
Trading Metrics:
| Open: | 28.5 | Previous Close: | 28.55 | |
| Day Low: | 28.22 | Day High: | 28.75 | |
| Year Low: | 20.92 | Year High: | 28.75 | |
| Price Avg 50: | 26.95 | Price Avg 200: | 25.44 | |
| Volume: | 21.412M | Average Volume: | 43.116M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freePFE full analysis
Welcome to MARKETSNAP’s SWOT analysis for Pfizer, one of the heavyweights in the pharmaceutical world. If you’re a long-term investor looking to dig into what makes this giant tick, or what could trip it up, you’ve come to the right place. Today, we’re breaking down Pfizer’s strengths, weaknesses, opportunities, and threats, with a deep dive into their latest financials, recent developments, and what might be on the horizon. Let’s get started with a quick overview of where Pfizer stands right…
